65,437 trials
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 2192.00; 397.20 ng*hr/mL
Dehydration
Primary: Technical Challenges — 2; 3; 2; 2 participants
Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 2.2; 2.6 months — p=0.6873
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 2804.5; 2597.3 ng*hr/mL
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants (Par.) With Complete Remission (CR), Measured From Start of Treatment Until 3 Months After Last Infusion — 10; 15 participants
Pharmacokinetics · Cytochrome P-450 CYP2D6 · CYP3A4 Protein, Human
Primary: Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered…
Acne Vulgaris
Primary: Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to…
Staphylococcal Infections
Primary: Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline — 27…
Pharmacokinetics
Primary: Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS…
Advanced/Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival in the Subgroup of Participants With βIII-tubulin Positive Tumors — 4.27; 4.27 Months — p=0.5735
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
Schizophrenia
Primary: N-back Task - Reaction Time — 786; 684 msec — p=0.16
HIV Infections
Primary: Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE) — 13.2; 2.4; 6.3; 1.6 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 24 — -1.09; -0.88; -1.21; -1.20 Percentage of glycosylated hemoglobin